Predictors of progression in systemic sclerosis patients with interstitial lung disease

Oliver Distler1, Shervin Assassi2, Vincent Cottin3, Maurizio Cutolo4, Sonye K. Danoff5, Christopher P. Denton6, Jörg H.W. Distler7, Anna-Maria Hoffmann-Vold8, Sindhu R. Johnson9, Ulf Müller Ladner10, Vanessa Smith11,12, Elizabeth R. Volkmann13 and Toby M. Maher14,15

Affiliations: 1Dept of Rheumatology, University Hospital Zurich, Zurich, Switzerland. 2Dept of Rheumatology and Clinical Immunogenetics, McGovern Medical School, University of Texas, Houston, TX, USA. 3National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, UMR754, Lyon, France. 4Research Laboratory, Clinical Division of Rheumatology, Dept of Internal Medicine DIMI, University of Genoa, IRCCS Polyclinic Hospital San Martino, Genoa, Italy. 5Division of Pulmonary and Critical Care Medicine, Johns Hopkins Medicine, Baltimore, MD, USA. 6UCL Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital, London, UK. 7Dept of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany. 8Dept of Rheumatology, Oslo University Hospital, Oslo, Norway. 9Toronto Scleroderma Program, Dept of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, ON, Canada. 10Dept of Rheumatology and Clinical Immunology, Justus-Liebig University Giessen, Campus Kerckhoff, Bad Nauheim, Germany. 11Dept of Rheumatology, Ghent University Hospital, Ghent, Belgium. 12Dept of Internal Medicine, Ghent University, Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium. 13Dept of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA, USA. 14National Heart and Lung Institute, Imperial College London, London, UK. 15NIHR Respiratory Clinical Research Facility, Royal Brompton Hospital, London, UK.

Correspondence: Oliver Distler, University Hospital Zurich, Dept of Rheumatology, Gloriastr. 25, Zürich 8091, Switzerland. E-mail: oliver.distler@usz.ch

Lung function tests and chest imaging help predict who has SSc-associated ILD and whether it will progress. In the absence of standardised methods for doctors, we recommend a strategy that combines both lung function tests and chest imaging. http://bit.ly/2uK9ZD2

Cite this article as: Distler O, Assassi S, Cottin V, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J 2020; 55: 1902026 [https://doi.org/10.1183/13993003.02026-2019].

This single-page version can be shared freely online.

ABSTRACT Systemic sclerosis (SSc) is a systemic autoimmune disease affecting multiple organ systems, including the lungs. Interstitial lung disease (ILD) is the leading cause of death in SSc.

There are no valid biomarkers to predict the occurrence of SSc-ILD, although auto-antibodies against anti-topoisomerase I and several inflammatory markers are candidate biomarkers that need further evaluation. Chest auscultation, presence of shortness of breath and pulmonary function testing are important diagnostic tools, but lack sensitivity to detect early ILD. Baseline screening with high-resolution computed tomography (HRCT) is therefore necessary to confirm an SSc-ILD diagnosis. Once diagnosed with SSc-ILD, patients’ clinical courses are variable and difficult to predict, although certain patient characteristics and biomarkers are associated with disease progression. It is important to monitor patients with SSc-ILD for signs of disease progression, although there is no consensus about which diagnostic tools

Copyright ©ERS 2020. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
to use or how often monitoring should occur. In this article, we review methods used to define and predict disease progression in SSc-ILD.

There is no valid definition of SSc-ILD disease progression, but we suggest that either a decline in forced vital capacity (FVC) from baseline of $\geq 10\%$, or a decline in FVC of $5-9\%$ in association with a decline in diffusing capacity of the lung for carbon monoxide of $\geq 15\%$ represents progression. An increase in the radiographic extent of ILD on HRCT imaging would also signify progression. A time period of 1–2 years is generally used for this definition, but a decline over a longer time period may also reflect clinically relevant disease progression.